LUNG

• Introduction

  This lecture by Andrew Fisher discusses the major contemporary issues facing lung transplant recipient in achieving long-term survival. It describes activity and outcomes of lung transplantation around the world and the leading causes of post-transplant death with an emphasis on the impact of chronic lung allograft dysfunction (CLAD). The lecture covers the potential role of extra-corporeal photopheresis (ECP) in both the treatment and prevention of CLAD and the quality of the existing evidence before describing the currently recruiting randomised controlled trial of ECP for CLAD being discussed in the UK.
• 
  

  
  

  Application in different organs - Lung
  

  
  

• Self-assessment quiz

  Please take the following quiz to test your understanding of this lecture

• The Science of ECP in Solid Organ Transplantation programme: Lung Transplantation H5P

  Mark as done
• Suggested resources

• • Lung Transplantation. Christie JD, Van Raemdonck D, Fisher AJ. N Engl J Med. 2024 Nov 14;391(19):1822-1836.
  • The use of extracorporeal photopheresis in solid organ transplantation-current status and future directions. Barten MJ, Fisher AJ, Hertig A. Am J Transplant. 2024 Mar 14:S1600-6135(24)00208-9.
  • Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK). Fisher AJ, White M, Goudie N, et al.  BMJ Open Respir Res. 2024 May 9;11(1):e001995.